文献速递主动脉疾病外周动脉疾病

血管筛查参与者中药物预防潜力的相关因素:VIVA试验发现

Pharmacological Preventive Potential Among Attenders at Vascular Screening: Findings from the VIVA Trial.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-02-14

本研究基于VIVA试验筛查臂25 074名64-75岁男性,横断面分析显示,年龄>70岁、COPD、使用抗高血压药等因素与AAA和PAD筛查阳性后存在他汀/抗血小板药物预防潜力相关。部分亚组(如年龄>70岁、独居、低收入、COPD)参与率较低,提示未来筛查项目需针对这些亚组定制信息。

要点

  • 年龄>70岁、COPD、使用抗高血压药与AAA筛查阳性后药物预防潜力相关。
  • PAD筛查阳性后药物预防潜力与年龄>70岁、独居、低收入、COPD等相关。
  • 年龄>70岁、独居、低收入、COPD者参与率较低,需定制信息提高参与。

核心结论

  • 未来血管筛查项目可能受益于针对更可能获益但较少接受筛查的亚组定制信息。

研究设计与样本

  • 解释变量包括社会人口学、社会经济特征、合并症、用药及旅行距离,来自全国登记数据。
  • 结局包括筛查阳性、药物预防潜力和参与率,采用卡方检验和多因素logistic回归分析。

主要发现

  • AAA筛查阳性后药物预防潜力相关因素:年龄>70岁(OR 1.23,95%CI 1.00-1.51)、COPD(OR 2.22,95%CI 1.38-3.57)、使用抗高血压药(OR 1.37,95%CI 1.09-1.71)。
  • 联合血管筛查中,年龄>70岁、独居、低收入、COPD、使用抗高血压药与药物预防潜力相关。
  • 上述亚组中,年龄>70岁、独居、低收入、COPD、使用抗糖尿病药与较低参与率相关。

临床怎么用

  • 识别具有药物预防潜力的亚组(如年龄>70岁、COPD、使用抗高血压药),针对性地提供筛查信息以提高参与率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Findings from the Viborg Vascular (VIVA) trial show a mortality benefit of multi-faceted vascular screening which was mainly ascribed to the initiation of prophylactic medication. However, the pharmacological preventive potential, which exists when individuals have a positive screening test result and do not already use statins and anti-platelet agents, has not been analysed. The aim of this study was to investigate factors associated with a pharmacological preventive potential of statins and anti-platelet agents among attenders vascular screening for abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). METHODS: This cross-sectional study used data from the VIVA trial screening arm including 25 074 men aged 64-75 years recruited between October 2008 and January 2011. Explanatory variables comprised socio-demographic- and socio-economic characteristics, comorbidities, medication use, and travel distance derived from nationwide registries. Outcomes included a positive screening test result, a pharmacological preventive potential, and attendance. Associations between the explanatory variables and the outcomes were investigated using the chi-square test and multivariate logistic regression. RESULTS: The factors most likely to be associated with a pharmacological preventive potential for positive AAA screening comprised age >70 years (odds ratio (OR) 1.23, 95% confidence interval 1.00-1.51), existing chronic obstructive pulmonary disease (COPD) (OR 2.22, 95% CI 1.38-3.57), and use of anti-hypertensives (OR 1.37, 95% CI 1.09-1.71). For positive PAD screening age >70 years (OR 1.41, 95% CI 1.25-1.60), living alone (OR 1.34, 95% CI 1.14-1.56), low income, COPD (OR 2.13, 95% CI 159-283), use of anti-hypertensives (OR 1.14, 95% CI 1.00-1.29) or anti-diabetics (OR 1.12, 95% CI 1.01-1.28), and short travel distance were associated with a pharmacological preventive potential. For combined vascular screening, age >70 years, living alone, low income, COPD, and use of anti-hypertensives were associated with a pharmacological preventive potential. Among these subgroups, lower attendance was associated with age >70 years, living alone, low income, COPD, and use of anti-diabetics. CONCLUSION: Future vascular screening programmes might benefit from tailoring information to subgroups who are more likely to benefit from screening but less likely to accept an offer.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hansen TB, Søgaard R, Lindholt JS, et al. Pharmacological Preventive Potential Among Attenders at Vascular Screening: Findings from the VIVA Trial. Eur J Vasc Endovasc Surg. 2020. PMID: 32063462. doi:10.1016/j.ejvs.2019.12.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。